A new peer-reviewed study published in PLOS One has provided evidence that pentosan polysulfate sodium (PPS) delivers sustained clinical, functional, and structural benefits in osteoarthritis, reinforcing its potential as a disease-modifying therapy.
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 Australian Biotech
Latest Video
New Stories
-
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News -
Tiny fragments of RNA, a giant opportunity for autoimmune disease treatment
February 10, 2026 - - Australian Biotech -
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech

